Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07159815

REACT - Resistance Exercise After Cancer Treatment

Resistance exercise has been shown to improve several important health variables after cancer and cancer related treatment, but unfortunately the adherence to resistance exercise is low. Typical reported exercise barriers are inconvenient location (e.g. long distance from home), exercise at an unfavorable time of the day, inadequate access to cancer-specific exercise and insufficient recommendations from healthcare providers. Thus, there is need for more research on resistance exercise with an alternative approach in cancer rehabilitation, that potentially can target a broad range of patients, despite their domicile. In Norway, the foundation "Active against cancer" has established exercise locations targeting cancer patients in several hospitals, and today they also offer digital home-based exercise sessions. Therefore, the overall research objectives are to compare the efficacy of a 12 weeks digital, home-based resistance exercise program for cancer patients after treatment on functional, mental, and metabolic health, compared to the same program conducted in a studio under guidance of an instructor. The primary aim is to compare the effect on exercise adherence between digital home-based exercise program and the on-site guided program in cancer patients after treatment. Secondary aims are to compare the two groups on several functional health outcomes, mental health outcomes and metabolic health markers. In addition to the randomized controlled trial, the project includes two non-randomized cohorts - patients undergoing active cancer treatment, and patients living more than 20 km from an exercise location - who follow the digital home-based program and the same test protocol.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Innlandet Hospital Trust/ Pusterommet Gjøvik, Gjøvik, Norway

Loading trial locations.

About this study

The project is an assessor-blinded randomized controlled trial investigating whether a 12-week digital, home-based resistance exercise program is equivalent to the same program delivered on-site under instructor guidance, for cancer patients after treatment. The primary outcome is exercise adherence; secondary outcomes cover functional, mental, and metabolic health.

Eligible participants living within 20 km of an exercise location (Lillehammer, Gjøvik, or Hamar) are stratified by sex and randomized 1:1 (block size 10) to digital home-based or on-site resistance exercise. Both arms perform the identical program: two 40-minute full-body sessions per week for 12 weeks (24 sessions total).

In addition to the RCT, the project includes two non-randomized reference groups that undergo the same test protocol and the digital home-based intervention only: (i) patients undergoing active cancer treatment, and (ii) eligible patients after treatment living more than 20 km from an on-site location. These reference groups support additional analyses of adherence and health benefits in patients who are undergoing active treatment or for whom on-site attendance is impractical.

The trial is designed and powered as an equivalence study: the central hypothesis is that home-based delivery achieves adherence, and functional, mental, and metabolic health benefits, equivalent to on-site delivery. Outcomes are assessed at baseline and within two weeks after the intervention, and again at approximately 12 months after inclusion to capture long-term effects. Recruitment and intervention are delivered across multiple periods (a 2023 pilot, followed by main periods in 2024 and 2025, with a further period in 2026) to accumulate sufficient participants.

The randomized controlled trial targets 120 participants, with 60 allocated to each arm (digital vs on-site). The two non-randomized reference groups are enrolled in addition to the trial; their size is not fixed in advance, as enrollment depends on the number of eligible patients identified during the recruitment periods.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥ 18 years and able to give informed consent
  • Previously diagnosed with any form of cancer and having completed systemic chemotherapy, immunotherapy or targeted therapies or local radiotherapy not more than 5 years earlier
  • Living within 20 km of one of the exercise locations (Lillehammer, Gjøvik, or Hamar)
  • Life expectancy of more than 12 months
  • Access to digital equipment at home (e.g. PC and/or tablet) and an email address, enabling participation on the digital exercise platform
  • Able to understand the Norwegian language

Exclusion criteria

  • Co-morbidities prohibiting exercise according to the protocol, such as serious cardiac, pulmonary, or other organ diseases
  • Conditions caused by the cancer that prohibits exercise, such as recent major surgery, fractures, or pain
  • Still undergoing active cancer treatment
  • Life expectancy of less than 12 months
  • Reduced mental capacity such that the participant is unable to give informed consent and follow the program
  • Has performed regular strength training (two or more times per week) within the last three months

Note on reference groups:

In addition to the randomized controlled trial, the study includes two non-randomized reference groups that are allocated to the digital home-based intervention only and undergo the same test protocol as the randomized participants. These are: (i) patients undergoing active cancer treatment, and (ii) patients who have completed treatment but live more than 20 km from an exercise location. Reference-group participants must otherwise meet the same inclusion criteria regarding age, cancer diagnosis, life expectancy, digital access, and language, and are subject to the same exclusion criteria, except that ongoing active treatment and distance from an exercise location are permitted as defining features of the respective groups. Patients undergoing active cancer treatment that is expected to confer a high risk of bone marrow suppression - leading to infections, bleeding, and/or severely reduced physical capacity - are excluded.

Treatment and study plan

Digital follow-up

Other

See the arm/group description.

Other names: Cancer rehabilitation, digital follow-up

On-site follow-up

Other

See the arm/group description.

Other names: On-site cancer rehabilitation, on-site follow-up

Resistance exercise

Behavioral

See the arm/group description.

Other names: Cancer rehabilitation

Primary outcomes

  1. Exercise adherence

    Time frame: Baseline to post-test (0-12 weeks)

    Percentage of completed prescribed exercise sessions.

Secondary outcomes

  1. Sustained exercise behaviour (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Self-reported resistance exercise behaviour at long-term follow-up, measured to assess maintenance of exercise after the supervised 12-week intervention period. Assessed using the physical activity registration questionnaire.

  2. Fatigue

    Time frame: Baseline to post-test (0-12 weeks)

    Fatigue measured using "Chalder's Fatigue" questionnaire. This is 11 item questionnaire, where respondents first answer with a 1 or a 0 to indicate if the question apply to them or not, and then there is a Likert scale from 0 to 3 indicating each statement from "less than usual" to "much more than usual". The first part indicates the number of symptoms, and the other part the intensity of the symptoms. The global score can range from 0-33, where higher score indicates more fatigue.

  3. Fatigue (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Fatigue measured using "Chalder's Fatigue" questionnaire. This is 11 item questionnaire, where respondents first answer with a 1 or a 0 to indicate if the question apply to them or not, and then there is a Likert scale from 0 to 3 indicating each statement from "less than usual" to "much more than usual". The first part indicates the number of symptoms, and the other part the intensity of the symptoms. The global score can range from 0-33, where higher score indicates more fatigue.

  4. Health-related Quality of Life: SF-36 questionnaire

    Time frame: Baseline to post-test (0-12 weeks)

    Quality of life will be measured using the Short Form Health Survey (SF-36 questionnaire). SF-36 include 36 questions, covering eight domains of health. Each domain has a score being converted and pooled using a scoring key, indicating high or low quality of life. Likert scales and yes/no options are used in the questionnaire. The score in SF-36 are standardized in a two-step process by the SF-36v2 software, to obtain a scoring algoritm from 0-100. A higher score indicates better health state, and a score of 50 have been proposed as a normative value.

  5. Health-related Quality of Life: SF-36 questionnaire (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Quality of life will be measured using the Short Form Health Survey (SF-36 questionnaire). SF-36 include 36 questions, covering eight domains of health. Each domain has a score being converted and pooled using a scoring key, indicating high or low quality of life. Likert scales and yes/no options are used in the questionnaire. The score in SF-36 are standardized in a two-step process by the SF-36v2 software, to obtain a scoring algoritm from 0-100. A higher score indicates better health state, and a score of 50 have been proposed as a normative value.

  6. Cancer-related quality of life

    Time frame: Baseline to post-test (0-12 weeks)

    Cancer-related quality of life will be measured using the European Organisation for Research and Treatment of Cancer Questionnaire (EORTC QLQ-C30 questionnaire), including five functional scales, three symptom scales, a global health status scale and six single items. All items range from 0 to 100, with a high scale score representing a higher response level, meaning a high score on the functional scale represents high level of functioning, a high score for the global health status represents high quality of life, but a high score on the symptom scale represents a high level of symptom.

  7. Cancer-related quality of life (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Cancer-related quality of life will be measured using the European Organisation for Research and Treatment of Cancer Questionnaire (EORTC QLQ-C30 questionnaire), including five functional scales, three symptom scales, a global health status scale and six single items. All items range from 0 to 100, with a high scale score representing a higher response level, meaning a high score on the functional scale represents high level of functioning, a high score for the global health status represents high quality of life, but a high score on the symptom scale represents a high level of symptom.

  8. Depression

    Time frame: Baseline to post-test (0-12 weeks)

    Despression measured using the "Patient Health Questionnaire" (PHQ9). PHQ9 is a Likert scale where respondens score 0-4 on the nine items (ranging from "not at all" to "nearly every day". The total number of points are 27, and score 20-27 indicate severe depression. A total score from 1-4 indicate minimal depression, a score 5-9 indicate mild depression, score 10-14 indicate moderate depression and 15-19 indicate moderately severe depression.

  9. Depression (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Despression measured using the "Patient Health Questionnaire" (PHQ9). PHQ9 is a Likert scale where respondens score 0-4 on the nine items (ranging from "not at all" to "nearly every day". The total number of points are 27, and score 20-27 indicate severe depression. A total score from 1-4 indicate minimal depression, a score 5-9 indicate mild depression, score 10-14 indicate moderate depression and 15-19 indicate moderately severe depression.

  10. Maximal muscle strength

    Time frame: Baseline to post-test (0-12 weeks)

    Maximal muscle strength measured using one repetition maximum test (1RM) in leg press (Keiser)

  11. Maximal muscle strength (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Maximal muscle strength measured using one repetition maximum test (1RM) in leg press (Keiser)

  12. Muscular endurance (legs)

    Time frame: Baseline to post-test (0-12 weeks)

    Muscular endurance measured using correctly performed number of repetitions at 70% of 1RM in leg press (Keiser)

  13. Muscular endurance (legs) (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Muscular endurance measured using correctly performed number of repetitions at 70% of 1RM in leg press (Keiser)

  14. Muscular endurance (upper body)

    Time frame: Baseline to post-test (0-12 weeks)

    Muscular endurance measured as correctly performed number of repetitions (push-ups)

  15. Muscular endurance (upper body) (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Muscular endurance measured as correctly performed number of repetitions (push-ups)

  16. Functional fitness, six minutes step test

    Time frame: Baseline to post-test (0-12 weeks)

    Functional fitness measured using the "six minutes step" test

  17. Functional fitness, six minutes step test (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Functional fitness measured using the "six minutes step" test

  18. Muscle mass, DXA scan

    Time frame: Baseline to post-test (0-12 weeks)

    Muscle mass measured using the whole-body DXA scan

  19. Muscle mass, DXA scan (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Muscle mass measured using the whole-body DXA scan

  20. Visceral fat mass, DXA scan

    Time frame: Baseline to post-test (0-12 weeks)

    Visceral fat mass measured using the whole-body DXA scan

  21. Visceral fat mass, DXA scan (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Visceral fat mass measured using the whole-body DXA scan

  22. Fat mass, DXA scan

    Time frame: Baseline to post-test (0-12 weeks)

    Fat mass measured using the whole-body DXA scan

  23. Fat mass, DXA scan (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Fat mass measured using the whole-body DXA scan

  24. Bone mineral density, DXA scan

    Time frame: Baseline to post-test (0-12 weeks)

    Bone mineral density measured using the whole-body DXA scan

  25. Bone mineral density, DXA scan (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Bone mineral density measured using the whole-body DXA scan

  26. Muscle mass, ultrasound

    Time frame: Baseline to post-test (0-12 weeks)

    Muscle mass measured using ultrasound to detect muscle thivkness of m.vastus lateralis

  27. Muscle mass, ultrasound (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Muscle mass measured using ultrasound to detect muscle thivkness of m.vastus lateralis

  28. Lipoprotein profile (subclasses of LDL, HDL)

    Time frame: Baseline to post-test (0-12 weeks)

    Lipoprotein profile (subclasses of LDL, HDL) measured taking venous blood samples

  29. Lipoprotein profile (subclasses of LDL, HDL) (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Lipoprotein profile (subclasses of LDL, HDL) measured taking venous blood samples

  30. Blood pressure at rest

    Time frame: Baseline to post-test (0-12 weeks)

    Both systolic and diastolic blood pressure at rest measured using automated upper-arm blood pressure cuff

  31. Blood pressure at rest (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Both systolic and diastolic blood pressure at rest measured using automated upper-arm blood pressure cuff

  32. Fasting blood glucose

    Time frame: Baseline to post-test (0-12 weeks)

    Fasting blood glucose measured in serum

  33. Fasting blood glucose (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Fasting blood glucose measured in serum

  34. Glycated hemoglobin (HbA1c)

    Time frame: Baseline to post-test (0-12 weeks)

    Long-term blood glucose control measured as glycated hemoglobin (HbA1c) in venous blood samples

  35. Glycated hemoglobin (HbA1c) (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Long-term blood glucose control measured as glycated hemoglobin (HbA1c) in venous blood samples

  36. Waist circumference

    Time frame: Baseline to post-test (0-12 weeks)

    Circumference of the waist measured using measuring tape

  37. Waist circumference (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Circumference of the waist measured using measuring tape

  38. Glucose tolerance (c-peptide)

    Time frame: Baseline to post-test (0-12 weeks)

    Oral glucose tolerance test (c-peptide) using venous blood samples

  39. Glucose tolerance (c-peptide) (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Oral glucose tolerance test (c-peptide) using venous blood samples

  40. Glucose tolerance (glucose)

    Time frame: Baseline to post-test (0-12 weeks)

    Oral glucose tolerance test (glucose) using venous blood samples

  41. Glucose tolerance (glucose) (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Oral glucose tolerance test (glucose) using venous blood samples

  42. Triglycerides

    Time frame: Baseline to post-test (0-12 weeks)

    Triglycerides measured in venous blood samples

  43. Triglycerides (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Triglycerides measured in venous blood samples

  44. Berg Balance Scale (BBS)

    Time frame: Baseline to post-test (0-12 weeks)

    Functional balance measured using the Berg Balance Scale (BBS). The scale consists of 14 tasks reflecting everyday balance demands, each scored by an assessor from 0 (unable to perform) to 4 (independent performance), giving a total score from 0 to 56. A higher score indicates better functional balance.

  45. Berg Balance Scale (BBS) (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Functional balance measured using the Berg Balance Scale (BBS). The scale consists of 14 tasks reflecting everyday balance demands, each scored by an assessor from 0 (unable to perform) to 4 (independent performance), giving a total score from 0 to 56. A higher score indicates better functional balance.

  46. C-reactive protein (CRP)

    Time frame: Baseline to post-test (12 weeks)

    Systemic inflammation measured as C-reactive protein (CRP) concentration in venous blood samples.

  47. C-reactive protein (CRP) (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Systemic inflammation measured as C-reactive protein (CRP) concentration in venous blood samples.

  48. Metabolic syndrome (collective assessment)

    Time frame: Baseline to post-test (12 weeks)

    Composite assessment of metabolic syndrome based on its established diagnostic components, including waist circumference, blood pressure, fasting blood glucose, triglycerides, and HDL cholesterol. Metabolic syndrome status is determined from the number of component criteria met.

  49. Metabolic syndrome (collective assessment) (12-month follow-up)

    Time frame: 12 months after inclusion (approximately)

    Composite assessment of metabolic syndrome based on its established diagnostic components, including waist circumference, blood pressure, fasting blood glucose, triglycerides, and HDL cholesterol. Metabolic syndrome status is determined from the number of component criteria met.

Sponsors and collaborators

Lead sponsor

Inland Norway University of Applied Sciences

Other

Collaborators

  • Sykehuset Innlandet HF

Registry information

Official study title

Comparing the Health Benefits of Digital Home-based Resistance Exercise and Supervised On-site Resistance Exercise in Cancer Patients After Treatment - a 12 Week RCT.

Acronym: REACT

Important dates

Study start
2023
Primary completion
2026
Study completion
2028
First posted
Sep 8, 2025
Registry last updated
Jun 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.